• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Building the global vaccine manufacturing capacity needed to respond to pandemics.建设应对大流行所需的全球疫苗生产能力。
Vaccine. 2021 Mar 19;39(12):1667-1669. doi: 10.1016/j.vaccine.2021.02.017. Epub 2021 Feb 24.
2
Global production capacity of seasonal and pandemic influenza vaccines in 2019.2019年季节性流感疫苗和大流行性流感疫苗的全球生产能力。
Vaccine. 2021 Jan 15;39(3):512-520. doi: 10.1016/j.vaccine.2020.12.018. Epub 2020 Dec 16.
3
Stakeholders' perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) - Results from a survey.利益相关者对《全球流感疫苗行动计划》（GAP）十年的看法——一项调查结果
Vaccine. 2016 Oct 26;34(45):5393-5399. doi: 10.1016/j.vaccine.2016.08.040. Epub 2016 Sep 16.
4
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.人畜共患流感病毒的抗原和基因特征以及用于大流行防范的候选疫苗病毒的研发。
Wkly Epidemiol Rec. 2011 Oct 21;86(43):469-80.
5
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.人畜共患流感病毒的抗原和基因特征以及大流行防范候选疫苗病毒的研发。
Wkly Epidemiol Rec. 2012 Oct 19;87(42):401-12.
6
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.人畜共患流感病毒的抗原和基因特征以及大流行防范候选疫苗病毒的研发。
Wkly Epidemiol Rec. 2012 Mar 16;87(11):97-108.
7
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.人畜共患流感病毒的抗原和基因特征以及大流行防范候选疫苗病毒的研发。
Wkly Epidemiol Rec. 2014 Mar 14;89(11):105-15.
8
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.人畜共患流感病毒的抗原和基因特征以及大流行防范候选疫苗病毒的研发。
Wkly Epidemiol Rec. 2013 Oct 18;88(42):449-63.
9
Push needed for pandemic planning.需要推动大流行规划。
Bull World Health Organ. 2012 Nov 1;90(11):800-1. doi: 10.2471/BLT.12.021112.
10
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.人畜共患流感病毒的抗原和基因特征以及大流行防范候选疫苗病毒的研发。
Wkly Epidemiol Rec. 2013 Mar 15;88(11):117-25.

引用本文的文献

1
Quality by design for mRNA platform purification based on continuous oligo-dT chromatography.基于连续寡聚dT色谱法的mRNA平台纯化的质量源于设计。
Mol Ther Nucleic Acids. 2024 Sep 11;35(4):102333. doi: 10.1016/j.omtn.2024.102333. eCollection 2024 Dec 10.
2
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment.灵活疫苗生产能力的价值：价值驱动因素、估算方法以及卫生技术评估中价值认可的方法。
Pharmacoeconomics. 2024 Jul;42(Suppl 2):187-197. doi: 10.1007/s40273-024-01396-6. Epub 2024 May 31.
3
Pandemic preparedness requires collaboration between governments, funders and pharma.大流行防范需要政府、资助者和制药公司之间的合作。
Nat Med. 2023 Dec;29(12):2999-3001. doi: 10.1038/s41591-023-02664-2.
4
Outlook of pandemic preparedness in a post-COVID-19 world.新冠疫情后世界大流行防范的展望。
NPJ Vaccines. 2023 Nov 20;8(1):178. doi: 10.1038/s41541-023-00773-0.
5
Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries.扩大全球疫苗生产能力：小国的战略优先事项
PLOS Glob Public Health. 2023 Jun 29;3(6):e0002098. doi: 10.1371/journal.pgph.0002098. eCollection 2023.
6
'Anarchist technologies': Anarchism, cybernetics and mutual aid in community responses to the COVID-19 crisis.“无政府主义技术”：无政府主义、控制论与社区应对新冠疫情危机中的互助
Organization (Lond). 2023 Jan;30(1):193-209. doi: 10.1177/13505084221090632. Epub 2022 May 2.
7
Common Demand vs. Limited Supply-How to Serve the Global Fight against COVID-19 through Proper Supply of COVID-19 Vaccines.常见需求与有限供应——如何通过新冠疫苗的合理供应来支持全球抗击新冠疫情。
Int J Environ Res Public Health. 2022 Jan 25;19(3):1339. doi: 10.3390/ijerph19031339.
8
Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.发展中国家疫苗生产能力建设：前进之路。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2020529. doi: 10.1080/21645515.2021.2020529. Epub 2022 Jan 27.
9
Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned.通过佐剂技术转让加强大流行性流感防范：挑战与经验教训
Vaccines (Basel). 2021 May 5;9(5):461. doi: 10.3390/vaccines9050461.

本文引用的文献

1
The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.迈向 COVID-19 群体免疫的漫长道路：疫苗平台技术和大规模免疫策略。
Front Immunol. 2020 Jul 21;11:1817. doi: 10.3389/fimmu.2020.01817. eCollection 2020.
2
From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?从 COVID-19 研究到疫苗应用：为什么需要 17 个月而不是 17 年，以及有哪些更广泛的教训？
Health Res Policy Syst. 2020 Jun 8;18(1):61. doi: 10.1186/s12961-020-00571-3.
3
Stakeholders' perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) - Results from a survey.利益相关者对《全球流感疫苗行动计划》（GAP）十年的看法——一项调查结果
Vaccine. 2016 Oct 26;34(45):5393-5399. doi: 10.1016/j.vaccine.2016.08.040. Epub 2016 Sep 16.
4
The 2015 global production capacity of seasonal and pandemic influenza vaccine.2015年季节性流感疫苗和大流行性流感疫苗的全球生产能力。
Vaccine. 2016 Oct 26;34(45):5410-5413. doi: 10.1016/j.vaccine.2016.08.019. Epub 2016 Aug 13.
5
Influenza vaccine production for the U.S. market.
Biosecur Bioterror. 2009 Sep;7(3):259-63. doi: 10.1089/bsp.2009.0921.
6
Incentives for biodefense countermeasure development.生物防御对策研发的激励措施。
Biosecur Bioterror. 2007 Sep;5(3):228-38. doi: 10.1089/bsp.2007.0030.

Building the global vaccine manufacturing capacity needed to respond to pandemics.

作者信息

Sell Tara Kirk, Gastfriend Daniel, Watson Matthew, Watson Crystal, Richardson Lauren, Cicero Anita, Inglesby Tom, Connell Nancy

机构信息

Johns Hopkins Center for Health Security, Johns Hopkins Bloomberg School of Public Health, United States.

出版信息

Vaccine. 2021 Mar 19;39(12):1667-1669. doi: 10.1016/j.vaccine.2021.02.017. Epub 2021 Feb 24.

DOI:10.1016/j.vaccine.2021.02.017
PMID:33640143
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7903906/
Abstract
摘要